In-Silico Drug Discovery Market by Molecule Type, Workflow, Therapeutic Area, End User

Description

List of Tables

[195 Pages Report] The In-Silico Drug Discovery Market size was estimated at USD 2.69 billion in 2023 and expected to reach USD 2.86 billion in 2024, at a CAGR 8.71% to reach USD 4.83 billion by 2030.

Global In-Silico Drug Discovery Market

KEY MARKET STATISTICS
Base Year [2023]	USD 2.69 billion
Estimated Year [2024]	USD 2.86 billion
Forecast Year [2030]	USD 4.83 billion
CAGR (%)	8.71%

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the In-Silico Drug Discovery Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the In-Silico Drug Discovery Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the In-Silico Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abzena Ltd., Aragen Life Sciences Pvt. Ltd., BioDuro LLC, BioNTech SE, Certara, Inc., Charles River Laboratories International, Inc., Chemical Computing Group ULC, ChemPartner PharmaTech Co Ltd, Creative Biostructure, Curia Global Inc., Evotec SE, GenScript Biotech Corporation, InSilico Medicine, Ligand Pharmaceuticals Incorporated, Schrodinger Inc., Selvita S.A., Simulations Plus, Inc., Sygnature Discovery, Viva Biotech Holding Group, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the In-Silico Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

Molecule Type
- Antibodies
- Nucleic Acids
- Peptides
- Proteins
- Vectors
Workflow
- Bioinformatics
- Clinical Trials
- Discovery
- Preclinical Tests
- Protein Structure Prediction
- Reverse Docking
- Target Identification
Therapeutic Area
- Blood Disorders
- Infectious Diseases
- Mental Disorders
- Metabolic Disorders
- Musculoskeletal Disorders
- Neurological Disorders
- Oncological Disorders
- Respiratory Disorders
- Skin Disorders
End User
- Academic & Research Institutes
- Contract Research Organizations
- Pharmaceutical Manufacturers
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the In-Silico Drug Discovery Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the In-Silico Drug Discovery Market?

3. What are the technology trends and regulatory frameworks in the In-Silico Drug Discovery Market?

4. What is the market share of the leading vendors in the In-Silico Drug Discovery Market?

5. Which modes and strategic moves are suitable for entering the In-Silico Drug Discovery Market?

Product Code: MRR-2E76C3E47FE9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. In-Silico Drug Discovery Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of diseases and increase in drug discovery
  - 5.1.1.2. Improvement in computational models and simulations
  - 5.1.1.3. Inclination towards personalized medicine approach
- 5.1.2. Restraints
  - 5.1.2.1. Concerns associated with data integration
- 5.1.3. Opportunities
  - 5.1.3.1. Integration of advanced technologies in in-silico drug discovery
  - 5.1.3.2. Ongoing R&D to drive innovation in in-silico drug discovery
- 5.1.4. Challenges
  - 5.1.4.1. Complex process and dearth of skilled professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. In-Silico Drug Discovery Market, by Molecule Type

6.1. Introduction
6.2. Antibodies
6.3. Nucleic Acids
6.4. Peptides
6.5. Proteins
6.6. Vectors

7. In-Silico Drug Discovery Market, by Workflow

7.1. Introduction
7.2. Bioinformatics
7.3. Clinical Trials
7.4. Discovery
7.5. Preclinical Tests
7.6. Protein Structure Prediction
7.7. Reverse Docking
7.8. Target Identification

8. In-Silico Drug Discovery Market, by Therapeutic Area

8.1. Introduction
8.2. Blood Disorders
8.3. Infectious Diseases
8.4. Mental Disorders
8.5. Metabolic Disorders
8.6. Musculoskeletal Disorders
8.7. Neurological Disorders
8.8. Oncological Disorders
8.9. Respiratory Disorders
8.10. Skin Disorders

9. In-Silico Drug Discovery Market, by End User

9.1. Introduction
9.2. Academic & Research Institutes
9.3. Contract Research Organizations
9.4. Pharmaceutical Manufacturers

10. Americas In-Silico Drug Discovery Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific In-Silico Drug Discovery Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa In-Silico Drug Discovery Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Abzena Ltd.
- 14.1.2. Aragen Life Sciences Pvt. Ltd.
- 14.1.3. BioDuro LLC
- 14.1.4. BioNTech SE
- 14.1.5. Certara, Inc.
- 14.1.6. Charles River Laboratories International, Inc.
- 14.1.7. Chemical Computing Group ULC
- 14.1.8. ChemPartner PharmaTech Co Ltd
- 14.1.9. Creative Biostructure
- 14.1.10. Curia Global Inc.
- 14.1.11. Evotec SE
- 14.1.12. GenScript Biotech Corporation
- 14.1.13. InSilico Medicine
- 14.1.14. Ligand Pharmaceuticals Incorporated
- 14.1.15. Schrodinger Inc.
- 14.1.16. Selvita S.A.
- 14.1.17. Simulations Plus, Inc.
- 14.1.18. Sygnature Discovery
- 14.1.19. Viva Biotech Holding Group
- 14.1.20. WuXi AppTec
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing